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OBJECTIVES: To evaluate whether risk scores used to classify patients with primary myelofibrosis and JAK-2
V617F mutation status can predict clinical outcome.
METHODS: A review of clinical and laboratory data from 74 patients with primary myelofibrosis diagnosed
between 1992 and 2011. The IPSS and Lille scores were calculated for risk stratification and correlated with
overall survival.
RESULTS: A V617F JAK2 mutation was detected in 32 cases (47%), with no significant correlation with overall
survival. The patients were classified according to the scores: Lille - low, 53 (73.%); intermediate, 13 (18%); and
high, 5 (7%); and IPSS – low, 15 (26%); intermediate-1, 23 (32%); intermediate-2, 19 (26%); and high, 15 (31%).
Those patients presenting a higher risk according to the IPSS (high and intermediate-2) had a significantly
shorter overall survival relative to the low risk groups (intermediate-1 and low) (p=0.02).
CONCLUSIONS: These results emphasize the importance of the IPSS prognostic score for risk assessment in
predicting the clinical outcome of primary myelofibrosis patients.
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& INTRODUCTION
Primary myelofibrosis (PMF) is a clonal hematopoietic
stem cell disorder characterized by bone marrow fibrosis,
extra-medullary hematopoiesis with splenomegaly and
leukoerythroblastosis in the peripheral blood (1,2). The
clinical manifestations of PMF include severe anemia,
marked hepatosplenomegaly and constitutional symptoms.
Ineffective erythropoiesis and extra-medullary hematopoi-
esis are the main causes of anemia and organomegaly,
respectively. Approximately 20% of patients diagnosed with
PMF may present progression to acute leukemia, but most
patients die of other conditions, such as cardiovascular
events, or as a consequence of cytopenias, such as infections
or bleeding (3).
The diagnostic criteria for this disease have been revised
since the discovery in 2005 of the acquired mutation V617F
in the JAK2 gene, which is found in 50-60% of patients with
PMF (4). The JAKs, which include JAK1, JAK2, JAK3 and
TYK, are a family of cytoplasmic tyrosine kinases that are
essential for cytokine signaling and gene transcription. The
JAK2V617F mutation results in the constitutive activation of
JAK2 tyrosine kinase and its downstream targets, which
leads to increased signaling of associated cytokine receptors
and the subsequent proliferation of hematopoietic cells
harboring these receptors (5). The clinical significance of the
mutation is evident in that homozygosis for JAK2 V617F
results in a more symptomatic illness relative to hetero-
zygous patients. However, the prognostic significance of the
mutation is controversial, including its implication in poor
clinical outcomes and the risk of progression to leukemia
(6).
Until recently, the most widely used prognostic classifica-
tion of PMF was the Lille score, which categorizes patients
into three risk groups based on the hemoglobin level and
leukocyte count at diagnosis (7). However, the Lille score
fails to clearly discriminate between intermediate- and high-
risk prognostic categories.
Recognition of these limitations led to a multicenter study
aimed at building a new International Prognostic Scoring
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System (IPSS) for PMF, in which seven European and
American centers contributed data from more than 1,000
PMF patients. In the multivariate analysis, the initial
features independently associated with a poor prognosis
were an age older than 65 years, the presence of constitu-
tional symptoms, hemoglobin ,10 g/dL, WBC count
.256109/L and the presence of blasts in the peripheral
blood. These prognostic factors formed the basis for four
risk groups with clear-cut, non-overlapping survival curves:
no factors (low risk), one factor (intermediate risk-1), two
factors (intermediate risk-2) or three or more factors (high
risk) (8).
The IPSS demonstrated a higher discriminatory power
than previous scoring systems and showed a high degree of
replicability and predictive accuracy. The IPSS is based on
prognostic factors recorded at the diagnosis of PMF that are
not necessarily stable over the course of the disease. To
address this shortcoming, a dynamic prognostic model
(DIPSS) was subsequently developed, and it utilizes the
same prognostic variables used in IPSS but can be applied at
any time during the course of the disease (9). The DIPSS
assigns two, rather than one, adverse points for hemoglobin
,10 g/dL, and the risk categorization is accordingly mod-
ified: low (0 adverse points), intermediate-1 (1 or 2 points),
intermediate-2 (3 or 4 points) and high (5 or 6 points).
As many patients are elderly at diagnosis or present
several comorbidities, most PMF patients are managed with
supportive care only. Thus, a high degree of prognostic
certainty is desired to permit the recommendation of more
aggressive or high-risk therapeutic procedures, and the
patient’s classification by prognostic score enables better
therapeutic planning, especially for patients who are
younger and eligible for bone marrow transplantation.
Furthermore, the development of methods to assess and
validate measures for clinical outcome becomes crucial in
the era of targeted therapies, in which the therapeutic
potential of JAK inhibitor molecules has emerged (10-12).
Thus, the aim of our study was to analyze the clinical and
laboratory data of consecutive PMF cases diagnosed in a
single center, focusing on the Lille and IPSS prognostic
scores and comparing their applicability to predict a poor
outcome.
& PATIENTS AND METHODS
Seventy-four consecutive patients with primary myelofi-
brosis diagnosed between January 1992 and August 2011
were included in this study for retrospective analysis. The
local ethics committee approved this study. All cases were
reclassified according to the WHO classification. In all cases,
the presence of increased reticulin and/or collagen bone
marrow content without any apparent cause (such as
chronic myeloid leukemia, PV, myelodysplasia, lympho-
proliferative disorders, scleroderma and primary pulmon-
ary hypertension) was required in addition to the presence
of features typical of this disease, including palpable
splenomegaly, leukoerythroblastosis or histological demon-
stration of myeloid metaplasia.
The variables selected for their prognostic significance
were assessed at diagnosis and included the following:
peripheral blood counts (hemoglobin, total leukocytes,
platelets and circulating blasts), splenomegaly, constitu-
tional symptoms (weight loss greater than 10% of the
baseline value in the year preceding the PMF diagnosis
and/or unexplained persistent fever or excessive sweating)
and myelofibrosis grade on a bone marrow biopsy based on
the Baumeister scale and karyotype obtained from the
marrow aspirate. JAK-2 mutation status was analyzed at
diagnosis or during the follow-up. The Lille and IPSS
prognostic scores were also calculated (Table 1).
Statistical analysis
Overall survival (OS) was calculated from the diagnosis
until the last follow-up or death, and transformation-free
survival (TFS) was calculated from diagnosis until the
progression to acute myeloid leukemia, last evaluation or
death. Survival curves were calculated using the log-rank
test (software Winstat 3.11 Statistics for Windows, version
3.1, Kalmia Co. Inc). Correlations between thrombosis and
the JAK2 mutation and between the myelofibrosis grade in
the bone marrow and IPSS were evaluated using the chi-
square test.
& RESULTS
Patient features at presentation
The main clinical and laboratory data of the 74 patients in
this study are summarized in Table 2. The median age at
diagnosis was 71.5 years. The hemoglobin level was ,10 g/
dL in 13 patients, the WBC was .256109/l in eight patients
and splenomegaly was found in 31 patients (42%).
Cytogenetic analysis was performed in 34 patients (46%),
and one case showed a partial deletion of chromosomes 13
and 15. The myelofibrosis grade based on the Baumeister
scale was available in 54 patients: 13 (24%) were classified as
grade 2, 27 (50%) as grade 3, and 14 (26%) as grade 4.
Treatment
Sixty-six patients (89%) received hydroxyurea (HU),
which was discontinued in six cases: three patients switched
Table 1 - Risk models for myelofibrosis applied in the
current study.
Risk
model Risk factors
Point per
factor Risk stratification
Lille Hb ,10 g/dL 1 Low: 0 points
WBC ,4 or .306109/l 1 Intermediate: 1 points
High: 2 points
IPSS Age .65 years Low: 0 points
Hb ,10 g/dL 1 Intermediate-1: 1 points
WBC .256109/l 1 Intermediate-2: 2 points
Circulating blasts $1% 1 High: 3 or more points
Constitutional symptoms 1
Table 2 - Clinical data of the primary myelofibrosis
patients (n = 74).
Demographics/Characteristics N
Age (median and range) 71.5 (31-92)
Presence of V617V JAK2 mutation 32 (47%)
Splenomegaly at diagnosis 31 (42%)
Hb (g/dL) (median and range) 12.2 (5.4-16.9)
Leucocytes/mm3 (median and range) 11.4 (0.9-47.3)
.30,000/mm3 2
,4000/mm3 6
Platelets (median and range) 456 (76-1.545)
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to anagrelide because of toxicity (lower limb ulcers), and
three patients switched to thalidomide and prednisone
because of therapeutic failure. Three patients were treated
only with supportive care (transfusion). Three patients
received no specific treatment during the course of this
study because they presented as clinically stable and had
blood counts similar to the normal range.
A splenectomy was performed in two patients, and three
others received splenic radiotherapy to control the symp-
toms. Only one patient was eligible for allogeneic bone
marrow transplantation, and he achieved complete remis-
sion, which was maintained by the end of this study (15
months of disease-free survival).
Thrombotic events were observed in 13 (18%) patients
(arterial occlusion in seven and venous thrombosis in six);
only one event occurred during thalidomide treatment.
There was no other relationship between these events and
the therapy applied or any other clinical or laboratory
variable.
V617F JAK2 mutation analysis
A V617F JAK2 mutation was detected in 32 cases (47%).
Patients with the mutation presented a shorter overall
survival (39% vs. 77%), although this difference was not
significant (p= 0.448) (Figure 1).
Risk stratification and clinical endpoints
According to the Lille score, most patients presented a
low risk (73.5%) (Table 2). The IPSS classification is
described in Table 3.
During the analysis period, 15 deaths were recorded: nine
due to infectious complications, three after a blast crisis
(occurring a median of 45 months after the diagnosis), and
three others by causes not related to the disease.
According to the Lille classification, no significant
difference was observed in overall survival (Figure 1).
However, in the IPSS data, patients classified in the high-
risk groups (high and int-2 scores) showed a significantly
lower overall survival than patients in the low-risk groups
(int-1 and low) (p= 0.02) (Figure 2).
There was no significant difference in overall survival
when patients were stratified according to myelofibrosis
grade (p=0.81). We did not find a correlation between
myelofibrosis grade and IPSS score (p= 0.59).
& DISCUSSION
Myelofibrosis is a myeloproliferative stem cell disorder
that is curable exclusively by allogeneic hematopoietic stem
cell transplantation. It also has substantial patient morbidity
and mortality, which results in an important need for
improved therapies. Recent advances in the understanding
of the pathogenetic mechanisms underlying this disease
have led to many clinical trials evaluating novel therapies,
such as ruxolitinib, which is the first JAK2 inhibitor
approved by the FDA for the treatment of patients with
intermediate- or high-risk myelofibrosis (13-15). Clinical
trials of these compounds have demonstrated improvement
Figure 1 - Overall survival of patients according to V617F JAK2 mutation status.
Table 3 - Risk stratification according to the Lille and IPSS
scores.
IPSS N
Low 15 (26%)
Intermediate-1 23 (32%)
Intermediate-2 19 (26%)
High 15 (31%)
Lille
Low 53 (73.5%)
Intermediate 13 (18%)
High 5 (7%)
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in constitutional symptoms and splenomegaly in patients
with both mutated and wild-type JAK2 PMF (16,17).
However, the development and validation of useful tools
to determine the prognosis and estimate survival is
necessary for better management of these patients.
Although the association was not significant, our findings
suggest that positivity for the JAK2 (V617F) mutation in our
group of patients may be associated with poorer survival.
Published data regarding the role of the JAK2 (V617F)
mutation in the prediction of the survival of PMF patients
reveal contradictory results. Campbell et al. showed that
patients positive for the mutation had a shorter overall
survival, even after correction for confounding factors
(p=0.01) (18). However, a recent study showed that a
positive qualitative test for the V617F mutation does not
predict survival but that patients with a lower V617F allele
burden presented a worse survival, which most likely
indicates the presence of an overriding V617F-negative
clone that confers a more aggressive disease phenotype
(19,20).
Although important for the differential diagnosis of PMF
with ET, the myelofibrosis grade based on the Baumeister
scale was not correlated with survival or the IPSS score.
Most of our patients presented with grade 3 or 4 (76%).
Our study also demonstrated that the IPSS is an
appropriate method for identifying patients with a worse
overall survival, which agrees with data from other studies
(8,9,21). Patients classified as high-risk (high and inter-
mediate-2 scores) showed a significantly lower overall
survival than low-risk patients (intermediate-1 and low
scores). In addition to demonstrating the efficacy of the IPSS
for prognosis evaluation in myelofibrosis, our results also
demonstrate the limitations of the Lille score in determining
risk for patients with a more severe disease. The Lille score
model was initially designed using 195 patients with PMF.
As described in other studies, the Lille score is capable of
identifying a well-defined group of patients with a good
prognosis but fails to clearly identify patients with a very poor
prognosis and those with an intermediate prognosis. This
issuemay be partially explained by the reliance of the score on
the hemoglobin level because leukopenia and leukocytosis
greater than 306109/L are infrequent at the time of the PMF
diagnosis (8,22). In fact, in our population, only two patients
presented leukocytosis greater than 306109/L, and six
presented with leukocytosis ,46109/L at diagnosis.
These findings corroborate the evidence indicating that
the IPSS must be evaluated for all patients recently
diagnosed as having PMF. In addition to predicting
survival, it is a helpful tool to evaluate therapeutic options;
it is easy to calculate and requires the evaluation of only
simple clinical and laboratory data. Other clinical trials
should be encouraged to better evaluate the influence of the
IPSS score in predicting the response to the new drugs
available for the treatment of PMF.
In summary, this study confirmed the importance of the
IPSS for risk factor stratification. Adjunctive treatment with
hydroxyurea is able to control low-risk patients in the
cellular phase of the disease. However, patients with
intermediate- and high-risk disease are candidates for other
therapeutic approaches, such as bone marrow transplanta-
tion or experimental drug therapies.
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